Skip to main content
Kane Biotech Inc. logo

Kane Biotech Inc. — Investor Relations & Filings

Ticker · KNE ISIN · CA4838092084 TSXV Manufacturing
Open in API
Filings indexed 218 across all filing types
Latest filing 2025-02-28 Management Reports
Country CA Canada
Listing TSXV KNE

About Kane Biotech Inc.

https://kanebiotech.com/

Kane Biotech Inc. is a biotechnology company engaged in the research, development, and commercialization of proprietary technologies designed to prevent and remove microbial biofilms, which are a major contributor to chronic infections and impaired healing. The company holds extensive intellectual property related to biofilm formation and dispersal mechanisms, utilizing proprietary technologies such as DispersinB® and coactiv+®. Its primary commercial focus is advanced wound care, where products like the revyve® Antimicrobial Wound Gel and Spray are designed to disrupt biofilms and promote healing. The product pipeline also includes surgical and dermatological applications for both human and animal health.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Management Reports Classification · 1% confidence The document is titled “Management Discussion and Analysis Quarterly Report – December 31, 2024” and consists entirely of MD&A commentary on the nine-month interim period, including forward-looking statements, explanations of results, business description and property updates. It references but does not itself contain the unaudited interim financial statements. This matches the definition for Management Reports (MDA) — management’s detailed discussion of financial results and outlook for a period shorter than a year.
2025-02-28 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian Material Change Report (Form 51-102F3) disclosing the completion of a non-brokered private placement offering (issuance of common shares, gross proceeds, finder’s fees, warrants). This is a financing activity update rather than a full annual/interim report or earnings release. It fits the definition of a Capital/Financing Update (CAP).
2025-02-21 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the second and final closing of a private placement of common shares by Kane Biotech, detailing the number of shares issued, price, gross proceeds, use of proceeds, hold period, and finder’s compensation. This falls squarely under capital/financing activities rather than an annual or interim report, earnings release, or other categories. Therefore, it is classified as a Capital/Financing Update (CAP).
2025-02-19 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release announcing an upcoming investor webinar (“Kane to Host Investor Webinar …”), outlining company strategy, milestones, and plans. It is not the actual detailed presentation but rather an event notice targeting investors. The closest matching filing category is Investor Presentation (IP).
2025-01-21 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the completion of a first closing of a non-brokered private placement of common shares and an extension of the offering deadline. It details the number of shares issued, insiders’ participation, use of proceeds, finder’s fees and warrants, and regulatory approvals. This is clearly an update on the company’s fundraising and financing activity (private placement), not a full financial report or management discussion, nor is it merely a notice of report publication. Therefore it falls under the Capital/Financing Update category (CAP).
2025-01-20 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a non-brokered private placement offering of up to 30,000,000 common shares to raise $3,000,000 for working capital and general corporate purposes. This is clearly an update on the company’s fundraising and capital structure change. It is neither an earnings release nor a regulatory filing or management change announcement, but a financing activity notice. Therefore, it fits the Capital/Financing Update category.
2024-12-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.